TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8198691

Group type: EXPERIMENTAL
Intervention: ACT training method
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Modelling training method
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both training methods
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 2467116

Group type: EXPERIMENTAL
Intervention: Amlodipine (mean daily dose 8.8 mg, range 5‐10 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Atenolol (mean daily dose 83.7 mg, range 50‐100 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 31851983

Group type: EXPERIMENTAL
Intervention: Nutritional interventions focusing on caloric intake and energy supplementation to prevent protein-energy wasting (PEW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malnutrition-inflammation score (KALANTAR Score)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrative approaches by physicians and dieticians
Number of subjects: 0
Study: 31597591

Group type: EXPERIMENTAL
Intervention: Support package including a website, printed booklet, and cognitive-behavioral therapy-based sessions delivered by a qualified practitioner
Number of subjects: 77
Study: 28623947

Group type: EXPERIMENTAL
Intervention: digital automated CBT‐I delivered by a web and/or mobile platform (in addition to treatment as usual (TAU))
Number of subjects: 404

Group type: COMPARATOR
Intervention: wait‐list control (in addition to TAU)
Number of subjects: 404
Study: 25922158

Group type: EXPERIMENTAL
Intervention: Back on Track intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: Primary care physiotherapy as usual
Number of subjects: 86
Study: 23535184

Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy
Number of subjects: 95
Study: 21277704

Group type: EXPERIMENTAL
Intervention: Intensive Role Induction (IRI)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: IRI+CM
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: IRI
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard Clinic Treatment (ST)
Number of subjects: 240
Study: 19098847

Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Regular colonoscopy (RC)
Number of subjects: 1000
Study: 16483155

Group type: EXPERIMENTAL
Intervention: Vasovasostomy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sperm concentration > 20 x 10(6)/ml
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sperm reappearance
Number of subjects: 88

Group type: COMPARATOR
Intervention: Pregnant group
Number of subjects: 88
Study: 15298643

Group type: EXPERIMENTAL
Intervention: Micafungin 12.5 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Micafungin 50 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Micafungin 75 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg
Number of subjects: 120
Study: 10767506

Group type: EXPERIMENTAL
Intervention: Roller-Ball ablation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Levonorgestrel IUD (MIRENA)
Number of subjects: 30
Study: 8863967

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 17

Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 17
Study: 1385919

Group type: EXPERIMENTAL
Intervention: Bupivacaine with sufentanil (group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bupivacaine with morphine (group B)
Number of subjects: 46
Study: 6741887

Group type: EXPERIMENTAL
Intervention: Rehearsal preparation procedure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual preparation (Control)
Number of subjects: 40
Study: 30009554

Group type: EXPERIMENTAL
Intervention: Outpatient psychotherapy
Number of subjects: 242
Study: 28485483

Group type: EXPERIMENTAL
Intervention: Self-affirmation manipulation (brief self-affirming exercise)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (identical questionnaire without self-affirming exercise)
Number of subjects: 50
Study: 25664775

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Memantine 40 mg
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 24268218

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 3687

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 3687
Study: 21135531

Group type: EXPERIMENTAL
Intervention: Nonpharmacological therapy (holistic cognitive rehabilitation program)
Number of subjects: 176

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 176
Study: 19799537

Group type: EXPERIMENTAL
Intervention: β-blockers (postoperative use)
Number of subjects: 2230

Group type: EXPERIMENTAL
Intervention: β-blockers (premedication)
Number of subjects: 2230
Study: 17448371

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 to 8 mg daily (n = 110)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo (PLB) (n = 114)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 224
Study: 15136193

Group type: EXPERIMENTAL
Intervention: Incredible Years Parent Training Program
Number of subjects: 882

Group type: COMPARATOR
Intervention: Usual Head Start services
Number of subjects: 882
Study: 11822997

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg at bedtime, titrated to 30 mg if needed)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9952093

Group type: EXPERIMENTAL
Intervention: Mepivacaine with arm abducted at 0 degrees
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mepivacaine with arm abducted at 90 degrees
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mepivacaine with digital compression
Number of subjects: 80
Study: 7723155

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1662

Group type: COMPARATOR
Intervention: Aggressive medical management (daily aspirin and risk factor management)
Number of subjects: 1662
Study: 2039284

Group type: EXPERIMENTAL
Intervention: Closed suction drainage
Number of subjects: 482

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Sump drainage
Number of subjects: 482
Study: 6458577

Group type: EXPERIMENTAL
Intervention: 0.5% topical thymoxamine hydrochloride
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 6734919

Group type: EXPERIMENTAL
Intervention: Desoxymethasone solution 0.25% with salicylic acid 1% and polyol‐fatty esters in ethanolic solution (Ibaril)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Betamethasone valerate solution 0.1% (Betnovat)
Number of subjects: 40
Study: 28473213

Group type: EXPERIMENTAL
Intervention: Topical ice slush cooling
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cold cardioplegic arrest without ice slush (Control)
Number of subjects: 20
Study: 27179830

Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided care
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard of care HF management
Number of subjects: 151
Study: 25546925

Group type: EXPERIMENTAL
Intervention: Caloric diet (group II)
Number of subjects: 201

Group type: COMPARATOR
Intervention: No special diet (group III)
Number of subjects: 201
Study: 21838789

Group type: EXPERIMENTAL
Intervention: BAY 60‐5521 (5 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BAY 60‐5521 (25 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BAY 60‐5521 (50 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BAY 60‐5521 (all doses)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 18354392

Group type: EXPERIMENTAL
Intervention: Fenfluramine (FEN)
Number of subjects: 7
Study: 18777700

Group type: EXPERIMENTAL
Intervention: Transmucosal implants with immediate restoration using provisional crowns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 16107978

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (n=30)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Vehicle cream (n=17)
Number of subjects: 47
Study: 14651137

Group type: EXPERIMENTAL
Intervention: HLA class II‐DR antigens DRB1*15XX
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HLA class II‐DR antigens DRB1*11XX
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HLA class II‐DR antigens DRB1*13XX
Number of subjects: 26
Study: 10493456

Group type: EXPERIMENTAL
Intervention: 600 mg ipriflavone daily for 12 months
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 1 microg vitamin D3 daily for 12 months
Number of subjects: 103

Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 103
Study: 8672854

Group type: EXPERIMENTAL
Intervention: Taxotere (docetaxel) at 100 mg/m2 administered in 1 hour perfusion every 21 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPT 11 (irinotecan) at 100-150 mg/m2/week via weekly infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPT 11 (irinotecan) at 350 mg/m2 every three weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPT 11 (irinotecan) at 500 mg/m2 with drug support against diarrhea
Number of subjects: 0
Study: 1717782

Group type: EXPERIMENTAL
Intervention: 2.5 mg cilazapril
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 5 mg cilazapril
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 6635104

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide + 5 mg amiloride (control group)
Number of subjects: 19
Study: 30817466

Group type: EXPERIMENTAL
Intervention: Intensive treatment of SBP to less than 120 mmHg (SPRINT)
Number of subjects: 12743

Group type: EXPERIMENTAL
Intervention: Intensive treatment of SBP to less than 120 mmHg (THIN)
Number of subjects: 12743
Study: 30446875

Group type: EXPERIMENTAL
Intervention: Jumping intervention (INT-SWI)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Jumping intervention (INT-CYC)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Jumping intervention (INT-FOO)
Number of subjects: 93
Study: 26865650

Group type: EXPERIMENTAL
Intervention: School Breakfast Program (SBP) participation
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Purchasing from corner stores for breakfast
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Skipping breakfast
Number of subjects: 821

Group type: COMPARATOR
Intervention: Breakfast behaviors across food security levels
Number of subjects: 821
Study: 25095659

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Prograf and Advagraf) included in the immunodepression protocol (Group 1)
Number of subjects: 246

Group type: COMPARATOR
Intervention: No tacrolimus (Group 2)
Number of subjects: 246
Study: 22143874

Group type: EXPERIMENTAL
Intervention: Audiologist-driven fine tuning using NAL-NL1 prescription rule
Number of subjects: 73

Group type: COMPARATOR
Intervention: Patient-driven fine tuning using Amplifit II system
Number of subjects: 73
Study: 19160103

Group type: EXPERIMENTAL
Intervention: Oral brush biopsy (OralCDx)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Synchronous scalpel biopsy
Number of subjects: 75
Study: 17174102

Group type: EXPERIMENTAL
Intervention: Disulfiram (DIS) 400mg daily + Cognitive Behaviour Therapy (CBT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50mg daily + Cognitive Behaviour Therapy (CBT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 12
Study: 16372795

Group type: EXPERIMENTAL
Intervention: Group I (n=18) used the same toothbrush for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Group II (n=18) replaced the toothbrush every month
Number of subjects: 36
Study: 11786588

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel 100 mg/m2
Number of subjects: 29

Group type: COMPARATOR
Intervention: 3-hour infusion of paclitaxel 100 mg/m2
Number of subjects: 29
Study: 9532549

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7989505

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transvaginal GIFT using a Jansen-Anderson tubal transfer set
Number of subjects: 87

Group type: COMPARATOR
Intervention: Transvaginal GIFT
Number of subjects: 87
Study: 3289947

Group type: EXPERIMENTAL
Intervention: felodipine 5 mg b.i.d. in addition to HCTZ 25 mg o.m.
Number of subjects: 81

Group type: COMPARATOR
Intervention: propranolol 80 mg b.i.d. in addition to HCTZ 25 mg o.m.
Number of subjects: 81
Study: 5773113

Group type: EXPERIMENTAL
Intervention: Amitriptyline + Alcohol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo + Alcohol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 21
Study: 31505515

Group type: EXPERIMENTAL
Intervention: Preferred Walking Speed (PWS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 23
Study: 27445063

Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrophilic acrylic IOL
Number of subjects: 120
Study: 25701337

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (1000 mg/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 23141152

Group type: EXPERIMENTAL
Intervention: Modafinil (300 mg/d)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 21406458

Group type: EXPERIMENTAL
Intervention: Tight control (TC) methotrexate-based strategy
Number of subjects: 299

Group type: COMPARATOR
Intervention: Conventional (CT) methotrexate-based strategy
Number of subjects: 299
Study: 19716589

Group type: EXPERIMENTAL
Intervention: Sperm treatment with exogenous platelet-activating factor (PAF)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No sperm treatment with exogenous platelet-activating factor (PAF)
Number of subjects: 92
Study: 17382426

Group type: EXPERIMENTAL
Intervention: True vertebral manipulations (VMG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham manipulations (sham-VMG)
Number of subjects: 64
Study: 15612842

Group type: EXPERIMENTAL
Intervention: Couples alcohol‐focused treatment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of alcohol‐focused spouse involvement and BCT
Number of subjects: 64

Group type: COMPARATOR
Intervention: Treatment for problem drinkers only (PDO)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Spouse behavioral support for drinking reduction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Relationship satisfaction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Drinking consequences
Number of subjects: 64
Study: 11589867

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily (monotherapy)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily + Unoprostone 0.12% twice daily (combination therapy)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Unoprostone 0.12% twice daily (monotherapy)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Unoprostone 0.12% twice daily + Latanoprost 0.005% once daily (combination therapy)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study: 9269606

Group type: EXPERIMENTAL
Intervention: 1 g of azithromycin
Number of subjects: 108

Group type: COMPARATOR
Intervention: 500 mg of ciprofloxacin
Number of subjects: 108
Study: 8324868

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg intravenous ondansetron
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg intravenous ondansetron
Number of subjects: 125

Group type: COMPARATOR
Intervention: 0.015 mg/kg intravenous ondansetron
Number of subjects: 125
Study: 3532655

Group type: EXPERIMENTAL
Intervention: Electrostimulation test (EST)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-electrostimulation test (non-EST)
Number of subjects: 100
Study: 30885800

Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST) plus TBI education
Number of subjects: 0

Group type: COMPARATOR
Intervention: TBI education alone
Number of subjects: 0
Study: 29895001

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 107
Study: 25662284

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: No statin therapy (Control)
Number of subjects: 51
Study: 24785989

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg, 6 hours before surgery and 5 mg per day after surgery for 2 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 22801019

Group type: EXPERIMENTAL
Intervention: CIC‐HFA 74 μg
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: CIC‐HFA 148 μg
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111
Study: 19647859

Group type: EXPERIMENTAL
Intervention: 3 applications of 3 ml 2% cidofovir in Intrasite gel in a cervical cap
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (the same volume of Intrasite alone)
Number of subjects: 53
Study: 17889767

Group type: EXPERIMENTAL
Intervention: CustomVue laser
Number of subjects: 39

Group type: COMPARATOR
Intervention: CustomCornea laser
Number of subjects: 39
Study: 15238279

Group type: EXPERIMENTAL
Intervention: 2 mg copper/L
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: 4 mg copper/L
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: 6 mg copper/L
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: > 6 mg copper/L
Number of subjects: 1365

Group type: COMPARATOR
Intervention: < 0.01 mg copper/L (control)
Number of subjects: 1365
Study: 11434226

Group type: EXPERIMENTAL
Intervention: Thought suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical participants
Number of subjects: 0
Study: 7706702

Group type: EXPERIMENTAL
Intervention: 40 min exercise on a stationary bicycle for 4 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: 10 min exercise on a stationary bicycle for 4 days
Number of subjects: 17
Study: 2689970

Group type: EXPERIMENTAL
Intervention: Ventilatory muscle endurance training (breathing through an inspiratory resistor equivalent to 85% SIP for 15 minutes twice daily, 5 days a week for 8 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both groups (pooled data)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 12
Study: 4557583

Group type: EXPERIMENTAL
Intervention: Propranolol (administered in 4 divided doses beginning 24 hours before and ending 2 hours prior to smoking)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (administered in 4 divided doses beginning 24 hours before and ending 2 hours prior to smoking)
Number of subjects: 0
Study: 31405532

Group type: EXPERIMENTAL
Intervention: Stretching regimen (three daily exercises to stretch the calves and hamstrings)
Number of subjects: 15
Study: 31455286

Group type: EXPERIMENTAL
Intervention: Cesarean hysterectomy (Group A, n=38)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cesarean section with cervical inversion and ligation of both uterine arteries (Group B, n=48)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Placenta left in place (Group C, n=16)
Number of subjects: 102
Study: 27461209

Group type: EXPERIMENTAL
Intervention: CT cohort (40 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Angiography cohort (40 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 80
Study: 25820848

Group type: EXPERIMENTAL
Intervention: Pilates exercises (5 times a week, 30 min per session for 8 weeks)
Number of subjects: 80
Study: 23550251

Group type: EXPERIMENTAL
Intervention: Structured home blood pressure monitoring education program
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 21418455

Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 82

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 82
Study: 19928397

Group type: EXPERIMENTAL
Intervention: FLC method
Number of subjects: 40

Group type: COMPARATOR
Intervention: FFT method
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Automated threshold search protocol using the FLC method
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simultaneous recording of ASSR for both the FFT and FLC method
Number of subjects: 40
Study: 16700202

Group type: COMPARATOR
Intervention: Oral analgesia (metamizol and oral morphine)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Periprosthetic nerve blockade with 2% mepivacaine
Number of subjects: 200
Study: 15214597

Group type: EXPERIMENTAL
Intervention: Moderate physical activity (PA) combined with weight loss and a balanced diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 0
Study: 10958216

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 9476695

Group type: EXPERIMENTAL
Intervention: Caffeine (0, 50, or 100 mg per hour for 5 hours, total of 0, 250, or 500 mg)
Number of subjects: 22
Study: 7885978

Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam 3 g
Number of subjects: 136

Group type: COMPARATOR
Intervention: Cefoxitin 2 g
Number of subjects: 136
Study: 2826611

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31789585

Group type: EXPERIMENTAL
Intervention: Cyberbullying perpetration
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1390
Study: 29511994

Group type: EXPERIMENTAL
Intervention: Oral branched-chain amino acids (BCAAs) for 28 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 18
Study: 26682691

Group type: EXPERIMENTAL
Intervention: Anserine/Carnosine Supplementation (ACS) 1.0 g daily for 3 months
Number of subjects: 39